EUCTR2006-000368-10-DE进行中（未招募）不适用
High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease. - Nexbac
Tecnical University of Munich0 个研究点目标入组 40 人开始时间: 2006年3月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with persistent reflux disorder with protone pump inhibitors in standard
- •Age between 18 – 70 years
- •unavailable contraindication of medicamentous therapy
- •none established disfunction of blood-coagulation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Participation on another clinical trial within 4 weeks bevor randomisation
- •linguistical or mental difficulties understanding
- •admit incompatibility of study medication
- •existent or planned pregnancy
- •clinical significant alterations of blood chemistry
- •„Alarme symptoms such as unintended loss of weight, hematemesis, melaena,
- •Oesophageal varices.
- •Tumors of upper gastrointestinal tract
研究者
相似试验
已完成
不适用
A study of first line therapy with esomeprazol for Helicobacter pylori eradicatioH.pylori infectionJPRN-UMIN000009642Kitasato University Kitasato Institute Hospital80
进行中（未招募）
不适用
Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion.Reserve Therapie der Helicobacter pylori InfectionMedDRA version: 8.1Level: LLTClassification code 10054263Term: Helicobacter infectionEUCTR2006-004323-10-DETechnische Universität Dresden
进行中（未招募）
1 期
A study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton pump inhibitor (PPI). An 8 week, open label, multicentre study. - RESPONSE studyGastroesophageal Reflux Disease (GORD)EUCTR2006-000257-22-GBAstraZeneca UK Ltd100
进行中（未招募）
不适用
„Einsatz des Beta-Blockers Esmolol in Kombination mit dem Phosphodiesterase-III-Hemmer Enoximon im Vergleich zur alleinigen Gabe von Esmolol zur Optimierung der Hämodynamik bei Patienten mit koronarer Herzkrankheit - Esmolol-Perfan StudieEUCTR2005-004617-15-DEKlinik für Anästhesiologie und Operative Intensivmedizin Klinikum Ludwigshafen
已完成
不适用
A prospective study of esomeprazole treatment for ulcer healing after gastric endoscopic submucosal dissectioearly gastric cancerJPRN-UMIN000010786niversity of Fukui Hospital200